Table 5.

Cause of mortality

Patient	Etiology	Length of usea	Reason for death	Response to PGI2
PGI2 use ≤72 hours
5	CLD	50	Care withdrawn	LR
8	CDH	5	Care withdrawn	LR
15	PPHN	72	Asystole	LR, SEb
23	Bronchiolitis	46.5	Care withdrawn	LR
28	CHD	2	Disease progression	LR, SEc
34	CLD	18.5	Care withdrawn	LR, SEc
Initiated after ECMO decannulation for deterioration
2	CDH	3	Care withdrawn	LR, SEb
4	CDH	17	Care withdrawn	LR
33	CDH	67	Clinical progression	LR
Initiated prior to ECMO decannulation
6	PPHN	17	Clinical progression	LR
12	IPAH	23.5	Multiorgan failure	LR, SEb
PGI2 use >72 hours
9	IPAH	3.96	Care withdrawn	RS, CP
14	CHD	5	Asystole	RS, CP
18	CLD	23	Care withdrawn	RS, CP
20	CDH	5	Care withdrawn	RS, CP
22	Bronchiolitis	12	Multiorgan failure	RS, CP
24	CDH	7	Care withdrawn	RS, CP
31	CLD	90	Septic shock	RS, CP
32	PPHN	31	Care withdrawn	RS, CP
Initiated after ECMO decannulation for deterioration
37	CDH	5.46	Clinical progression	RS, CP
Initiated prior to ECMO decannulation
30	CDH	3.75	Clinical progression	LR

^NotePGI2: prostacyclin; CLD: chronic lung disease; LR: lack of PGI2 response; CDH: congenital diaphragmatic hernia; PPHN: persistent pulmonary hypertension of the newborn; SE: side effect noted; ECMO: extracorporeal membrane oxygenation; IPAH: idiopathic pulmonary hypertension; RS: PGI2 response seen; CP: continued progression of disease.

^aData are hours for PGI2 use ≤72 hours and days for PGI2 use >72 hours.

^bHypotension requiring dose reduction.

^cCyanosis requiring discontinuation.